Celdara Medical (United States)

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Susanne H.C. Baumeister, Joana Murad, Lillian Werner et al. · Cancer Immunology Research · 2018 · 325 citations · Full text

Pharmacy, Immunology, Oncology +17

Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin

Monique Hinchcliff, Diana M. Toledo, Jaclyn Taroni et al. · Journal of Investigative Dermatology · 2018 · 66 citations · Full text

Medicine, Dermatology, Immunology +14

Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell–Treated Mice

Marie-Louise Sentman, Joana Murad, W. James Cook et al. · The Journal of Immunology · 2016 · 60 citations · Full text

Life Sciences, Immunology, Oncology +17

Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy

Joana Murad, Susanne H.C. Baumeister, Lillian Werner et al. · Cytotherapy · 2018 · 55 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

Sarah Nikiforow, Lillian Werner, Joana Murad et al. · Blood · 2016 · 40 citations

Medicine, Hematology, Oncology +17